Scinovex
review Open AccessTop 1% cited

The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases

International Journal of Molecular Sciences · 2020 · Vol. 21(24) · pp. 9739–9739
Griselda A. Cabral-PachecoIdalia Garza‐VelozClaudia Castruita-De la RosaJesus Manuel Ramirez-AcuñaBraulio A Perez-RomeroJesús F Guerrero-RodriguezNadia Martínez-AvilaMargarita L. Martínez‐Fierro

Abstract

Matrix metalloproteinases (MMPs) are a family of zinc-dependent extracellular matrix (ECM) remodeling endopeptidases that have the capacity to degrade almost every component of the ECM. The degradation of the ECM is of great importance, since it is related to embryonic development and angiogenesis. It is also involved in cell repair and the remodeling of tissues. When the expression of MMPs is altered, it can generate the abnormal degradation of the ECM. This is the initial cause of the development of chronic degenerative diseases and vascular complications generated by diabetes. In addition, this process has an association with neurodegeneration and cancer progression. Within the ECM, the tissue inhibitors of MMPs (TIMPs) inhibit the proteolytic activity of MMPs. TIMPs are important regulators of ECM turnover, tissue remodeling, and cellular behavior. Therefore, TIMPs (similar to MMPs) modulate angiogenesis, cell proliferation, and apoptosis. An interruption in the balance between MMPs and TIMPs has been implicated in the pathophysiology and progression of several diseases. This review focuses on the participation of both MMPs (e.g., MMP-2 and MMP-9) and TIMPs (e.g., TIMP-1 and TIMP-3) in physiological processes and on how their abnormal regulation is associated with human diseases. The inclusion of current strategies and mechanisms of MMP inhibition in the development of new therapies targeting MMPs was also considered.

Protease and Inhibitor MechanismsPeptidase Inhibition and AnalysisSignaling Pathways in DiseaseMatrix metalloproteinaseAngiogenesisExtracellular matrixCell biologyCancer researchNeurodegenerationMatrix metalloproteinase inhibitorProteolytic enzymesBiologyMedicine

MeSH terms

Chronic DiseaseDiabetes MellitusExtracellular MatrixHumansNeovascularization, PhysiologicTissue Inhibitor of MetalloproteinasesTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-3Matrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix Metalloproteinases
Citations
1,634
FWCI
48.19
field-weighted impact
References
454
Percentile
100%
vs. same field & year
Citations per year
References
Structure and function of matrix metalloproteinases and TIMPs
Cardiovascular Research · 2006 · 3,356 citations
New functions for the matrix metalloproteinases in cancer progression
Nature reviews. Cancer · 2002 · 6,034 citations
Global Prevalence of Diabetes
Diabetes Care · 2004 · 15,281 citations
Matrix metalloproteinases in inflammation
Biochimica et Biophysica Acta (BBA) - General Subjects · 2014 · 432 citations
Matrix metalloproteinases and the regulation of tissue remodelling
Nature Reviews Molecular Cell Biology · 2007 · 2,947 citations
Defining the clinical course of multiple sclerosis
Neurology · 2014 · 3,048 citations
Global cancer statistics
CA A Cancer Journal for Clinicians · 2011 · 55,006 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.